Treatment News : AIDS Cure Research: North Carolina Scientist Study Cancer Drug

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 3, 2010

AIDS Cure Research: North Carolina Scientist Study Cancer Drug

The search for an AIDS cure is about to take a new step as scientists begin human studies involving an existing but little-used cancer drug from Merck, reports Bloomberg News. David Margolis, MD, and his colleagues from the University of North Carolina in Chapel Hill hope the drug will take them further down the path of finally purging all HIV out of someone’s body, ultimately achieving a cure.

The drug, called Zolinza (vorinostat), is part of a family of drugs known as histone deacetylase (HDAC) inhibitors. Previous research found that Zolinza was able to flush out HIV that typically sits latent in resting CD4 cells in the body, waiting to bring an infection roaring back to life if an HIV-positive person stops taking his or her antiretroviral (ARV) drugs.

Margolis and a top researcher at Merck, Daria Hazuda, PhD, concede that the drug might be too toxic to ever make it as an HIV therapy, but they hope that Margolis’s proof-of-concept study will tell them whether they’re on the right track.

“It’s really all about trying to move the field ahead,” Margolis told Bloomberg News. “We don’t expect to cure anybody, but we expect to really show whether it can work the way we think it does in people—or not.”

The report goes on to detail the promise of HDAC inhibitors and then looks at a number of companies, including Gilead and Tibotec as well as Merck, that have “cure” research programs.

“Everybody has now come to the conclusion that it’s going to take a combination of different approaches,” Hazuda said. “Because there are HDAC inhibitors that are already licensed to treat other diseases, they may provide at least an anchor upon which to build a first-generation regimen.”

Some harbor lingering skepticism about ever eradicating HIV from the body, but Margolis remains undeterred.

“I’m 51,” Margolis said. “I’m not doing this because I think that I can’t succeed before I die.”

Search: HDAC inhibitors, histone deacetylase, Zolinza, vorinostat, David Margolis, reservoir, latent, cure, Daria Hazuda, Merck, cancer, Gilead, Tibotec

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (3 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.